Dyslipidemia

Dyslipidemia is one of the top 5 risk factors for cardiovascular disease, alongside hypertension, diabetes, smoking, and obesity.1 Several genetic phenotypes such as apolipoprotein E (APOE) result in variable serum lipid responses to diet, as well as contribute to cardiovascular disease.2 Recent studies suggest that increasing dietary cholesterol does not significantly alter serum total or LDL cholesterol levels or heart disease risk.3 Reducing refined carbohydrate intake such as sugars, bread, white potatoes, white rice, starches, and low fiber carbohydrates may be more important in improving serum lipids than altering intake of saturated fats and cholesterol.4-6 Expanded lipid profiles that measure lipids, lipid subfractions, particle size and number, and APOB and APOA are preferred over standard lipid profiles that measure only the total lipid levels.7

Although statins are heavily advertised to the general public as the cure-all for dyslipidemia, they have been linked to muscle pain, muscle weakness, abnormal liver function tests, neuropathy, memory loss, glucose intolerance and diabetes amongst many other side effects.8 Great results have been achieved through integrated therapy that emphasizes nutritional modification, dietary supplements, and exercise.9 Dietary supplements include niacin, red yeast rice, omega-3 fatty acids, soy, and flax seed amongst others.

At Rocky Mountain Regenerative Medicine, we have an in-depth understanding of dyslipidemia beyond the traditional measures used by many primary care providers. More importantly, we understand how to reduce those markers and in doing so, reduce risk of stroke and heart attacks.

  1. W.B. Kannel, W.D. Castelli, T. Gordon, et al.: Serum cholesterol, lipoproteins and risk of coronary artery disease. The Framingham Study. Ann Intern Med. 74:1-12 1971
  2. T. Neiminen, M. Kahonen, L.E. Viiri, et al.: Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease.Pharmacogenomics. 9:1475-1486 2008
  3. M. Houston: The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens (Greenwich). 14:121-132 2012
  4. M.C. Houston, S. Fazio, F.H. Chilton, et al.: Non pharmacologic treatment of dyslipidemia. One of the first and most comprehensive reviews on nutrition and supplements for the treatment of dyslipidemia with an extensive reference list. Multi-authored and authoritative review Prog Cardiovasc Dis. 52:61-94 2009
  5. L. Djousse, J.M. Caziano: Dietary cholesterol and coronary artery disease: a systematic review. Curr Atheroscler Rep. 11:418-422 2009
  6. P.W. Siri-Tarino, Q. Sun, F.B. Hu, et al.: Saturated fat, carbohydrate and cardiovascular disease. Am J Clin Nutr. 91:502-509 2010
  7. A.M. Hodge, A.J. Jenkins, D.R. English, et al.: NMR determined lipoprotein subclass profile is associated with dietary composition and body size. Nutr Metab Cardiovasc Dis. 21:603-609 2011
  8. E.J. Mills, P. Wu, G. Chong, et al.: Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 104:109-124 2011
  9. M. de Lorgeril, P. Salen: The Mediterranean diet: rationale and evidence for its benefit.Curr Atheroscler Rep. 10:518-522 2008